Kyverna Therapeutics, Inc.

Q: Jun 30 2026

Q: Mar 31 2026

FY: Dec 31 2025

Q: Sep 30 2025

Q: Jun 30 2025

Q: Mar 31 2025

FY: Dec 31 2024

Q: Sep 30 2024

Q: Jun 30 2024

Q: Mar 31 2024

FY: Dec 31 2023

Regulation FD Disclosure

Results of Operations and Financial Condition

Entry into a Material Definitive Agreement

Entry into a Material Definitive Agreement

Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Results of Operations and Financial Condition

Other Events

Regulation FD Disclosure

Regulation FD Disclosure

Regulation FD Disclosure

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Results of Operations and Financial Condition

Entry into a Material Definitive Agreement

Regulation FD Disclosure

Regulation FD Disclosure

Results of Operations and Financial Condition

Entry into a Material Definitive Agreement

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Registration statement under Securities Act of 1933

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement for Primary Offering

Free Writing Prospectus

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Prospectus Supplement for Primary Offering

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Registration statement under Securities Act of 1933

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Certification of approval for listing and registration on a national securities exchange

Prospectus Supplement with Pricing Information

Notice of Effectiveness

Amended Initial Registration Statement

Registration of Securities on Exchange

Amended Initial Registration Statement

Registration (IPO) statement under Securities Act of 1933

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Bain Capital Life Sciences Opportunities III, LP

BlackRock, Inc.

CLARK IAN T

Cohen Fred E

SEIDENBERG BETH C

Aktar Mert

Shaw Christi

Martini Gregory S.

Martini Gregory S.

Dac Nadia

Dac Nadia

Walker Karen Marie

Walker Karen Marie

SPIEGELMAN DANIEL K

SPIEGELMAN DANIEL K

Biddle Warner Weston

GEHCHAN NAJI

GRASSO MARC

Miller Andrew Craig

Miller Andrew Craig

Annual Report Scanned (Paper)

Correspondence with the SEC

Letter from the SEC

Annual Report Scanned (Paper)

Correspondence with the SEC

Letter from the SEC

Letter from the SEC

No description available

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

Draft registration statement (confidential submission) (amendment)

No description available

Letter from the SEC

No description available

Draft registration statement (confidential submission) (amendment)

No description available

Letter from the SEC